Soligenix, Inc. is a late-stage biopharmaceutical company. The Company develops product candidates in the areas of inflammation, oncology and biodefense. It operates in two segments: BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment is developing a first-in-class photo-dynamic therapy (SGX301) utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, formulations of oral beclomethasone 17,21-dipropionate for the prevention or treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201), and its innate defense regulator (IDR) technology (SGX942) for the treatment of oral mucositis. The Vaccines/BioDefense segment includes development programs for RiVax, its ricin toxin vaccine candidate, VeloThrax, an anthrax vaccine candidate, OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate and SGX943, a melioidosis therapeutic candidate.